Skip to main content

Table 3 Performance of diagnostic indices

From: Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers

Study

Index

Designed sensitivity

cutoff

Sensitivity (CI)

Specificity (CI)

Accuracy (CI)

AUC (CI)

TP

TN

FP

FN

Performance of diagnostic indices developed on PC vs. HS

PC vs. HS

I

0.85

−9.13

84.85 (78.45–89.95)

100.00 (90.00–100.00)

87.50 (82.10–91.74)

1.00 (1.00–1.00)

140

35

0

25

A-AC vs. HS

I

 

−9.13

74.58 (61.56–85.02)

100.00 (90.00–100.00)

84.04 (75.05–90.78)

0.99 (0.96–1.00)

44

35

0

15

DC vs. HS

I

 

−9.13

100.00 (54.07–100.00)

100.00 (90.00–100.00)

100.00 (91.40–100.00)

1.00 (1.00–1.00)

6

35

0

0

CBD vs. HS

I

 

−9.13

66.67 (43.03–85.41)

100.00 (90.00–100.00)

87.50 (75.93–94.82)

1.00 (0.99–1.00)

14

35

0

7

A-AC, DC, CBD vs. HS

I

 

−9.13

74.42 (63.87–83.22)

100.00 (90.00–100.00)

81.82 (73.78–88.24)

0.99 (0.97–1.00)

64

35

0

22

GC vs. HS

I

 

−9.13

100.00 (83.16–100.00)

100.00 (90.00–100.00)

100.00 (93.51–100.00)

1.00 (1.00–1.00)

20

35

0

0

PC vs. HS

II

0.85

16.68

84.85 (78.45–89.95)

100.00 (90.00–100.00)

87.50 (82.10–91.74)

1.00 (1.00–1.00)

140

35

0

25

A-AC vs. HS

II

 

16.68

67.80 (54.36–79.38)

100.00 (90.00–100.00)

79.79 (70.25–87.37)

0.94 (0.89–0.98)

40

35

0

19

DC vs. HS

II

 

16.68

83.33 (35.88–99.58)

100.00 (90.00–100.00)

97.56 (87.14–99.94)

1.00 (1.00–1.00)

5

35

0

1

CBD vs. HS

II

 

16.68

80.95 (58.09–94.55)

100.00 (90.00–100.00)

92.86 (82.71–98.02)

0.97 (0.90–1.00)

17

35

0

4

A-AC, DC, CBD vs. HS

II

 

16.68

72.09 (61.38–81.23)

100.00 (90.00–100.00)

80.17 (71.94–86.86)

0.95 (0.91–0.99)

62

35

0

24

GC vs. HS

II

 

16.68

95.00 (75.13–99.87)

100.00 (90.00–100.00)

98.18 (90.28–99.95)

0.96 (0.87–1.00)

19

35

0

1

PC vs. HS

III

0.85

149.10

84.85 (78.45–89.95)

100.00 (90.00–100.00)

87.50 (82.10–91.74)

1.00 (1.00–1.00)

140

35

0

25

A-AC vs. HS

III

 

149.10

72.88 (59.73–83.64)

100.00 (90.00–100.00)

82.98 (73.84–89.95)

0.98 (0.95–1.00)

43

35

0

16

DC vs. HS

III

 

149.10

66.67 (22.28–95.67)

100.00 (90.00–100.00)

95.12 (83.47–99.40)

1.00 (1.00–1.00)

4

35

0

2

CBD vs. HS

III

 

149.10

71.43 (47.82–88.72)

100.00 (90.00–100.00)

89.29 (78.12–95.97)

1.00 (0.99–1.00)

15

35

0

6

A-AC, DC, CBD vs. HS

III

 

149.10

72.09 (61.38–81.23)

100.00 (90.00–100.00)

80.17 (71.94–86.86)

0.99 (0.97–1.00)

62

35

0

24

GC vs. HS

III

 

149.10

100.00 (83.16–100.00)

100.00 (90.00–100.00)

100.00 (93.51–100.00)

1.00 (1.00–1.00)

20

35

0

0

Performance of diagnostic indices developed on PC vs. HS + CP

PC vs. HS + CP

IV

0.85

−9.13

84.85 (78.45–89.95)

75.68 (64.31–84.90)

82.01 (76.54–86.66)

0.89 (0.84–0.94)

140

56

18

25

A-AC vs. HS + CP

IV

 

−9.13

74.58 (61.56–85.02)

75.68 (64.31–84.90)

75.19 (66.96–82.26)

0.83 (0.76–0.90)

44

56

18

15

DC vs. HS + CP

IV

 

−9.13

100.00 (54.07–100.00)

75.68 (64.31–84.90)

77.50 (66.79–86.09)

0.85 (0.76–0.93)

6

56

18

0

4 vs. HS + CP

IV

 

−9.13

66.67 (43.03–85.41)

75.68 (64.31–84.90)

73.68 (63.65–82.19)

0.80 (0.71–0.88)

14

56

18

7

A-AC, DC, CBD vs. HS + CP

IV

 

−9.13

74.42 (63.87–83.22)

75.68 (64.31–84.90)

75.00 (67.55–81.50)

0.83 (0.76–0.89)

64

56

18

22

CG vs. HS + CP

IV

 

−9.13

100.00 (83.16–100.00)

75.68 (64.31–84.90)

80.85 (71.44–88.24)

0.97 (0.93–1.00)

20

56

18

0

PC vs. HS + CP

V

0.85

1.38

84.85 (78.45–89.95)

91.89 (83.18–96.97)

87.03 (82.10–91.01)

0.96 (0.94–0.98)

140

68

6

25

A-AC vs. HS + CP

V

 

1.38

77.97 (65.27–87.71)

91.89 (83.18–96.97)

85.71 (78.59–91.17)

0.93 (0.87–0.97)

46

68

6

13

DC vs. HS + CP

V

 

1.38

100.00 (54.07–100.00)

91.89 (83.18–96.97)

92.50 (84.39–97.20)

1.00 (0.98–1.00)

6

68

6

0

CBD vs. HS + CP

V

 

1.38

85.71 (63.66–96.95)

91.89 (83.18–96.97)

90.53 (82.78–95.58)

0.94 (0.89–0.98)

18

68

6

3

A-AC, DC, CBD vs. HS + CP

V

 

1.38

81.40 (71.55–88.98)

91.89 (83.18–96.97)

86.25 (79.93–91.18)

0.94 (0.89–0.97)

70

68

6

16

GC vs. HS + CP

V

 

1.38

95.00 (75.13–99.87)

91.89 (83.18–96.97)

92.55 (85.26–96.95)

0.99 (0.96–1.00)

19

68

6

1

PC vs. HS + CP

VI

0.85

1.46

84.85 (78.45–89.95)

93.24 (84.93–97.77)

87.45 (82.57–91.37)

0.97 (0.95–0.99)

140

69

5

25

A-AC vs. HS + CP

VI

 

1.46

72.88 (59.73–83.64)

93.24 (84.93–97.77)

84.21 (76.88–89.95)

0.92 (0.87–0.96)

43

69

5

16

DC vs. HS + CP

VI

 

1.46

100.00 (54.07–100.00)

93.24 (84.93–97.77)

93.75 (86.01–97.94)

0.99 (0.97–1.00)

6

69

5

0

CBD vs. HS + CP

VI

 

1.46

76.19 (52.83–91.78)

93.24 (84.93–97.77)

89.47 (81.49–94.84)

0.93 (0.87–0.98)

16

69

5

5

A-AC, DC, CBD vs. HS + CP

VI

 

1.46

75.58 (65.13–84.20)

93.24 (84.93–97.77)

83.75 (77.10–89.10)

0.93 (0.89–0.96)

65

69

5

21

GC vs. HS + CP

VI

 

1.46

75.00 (50.90–91.34)

93.24 (84.93–97.77)

89.36 (81.30–94.78)

0.91 (0.80–0.98)

15

69

5

5

  1. AUC Area under Curve, TP True positive, TN True negative, FP False positive, FN False negative, PC Pancreatic Cancer, A-AC Ampullary Adenocarcinoma, DC Duodenal Cancer, CBD Common bile duct cancer, GC Gastric cancer, HS Healthy subjects